Formycon Times and Sales

Formycon Aktie VALOR 12194189 / ISIN DE000A1EWVY8

63.97

CHF

-4.35

CHF

-6.37%

18:00:00

BRX

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch			Ausblick

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

Ausblick

Formycon Times and Sales (BRX)

Zeit	Kurs	Umsatz grafisch
Times and Sales Zur Zeit stehen keine Daten zur Verfügung
Kursrückgang	Kursanstieg	keine Kursänderung
(Balkenlänge beschreibt das Umsatzvolumen)

30.08.23		EQS-News: Formycon berichtet über erfolgreiches erstes Halbjahr 2023
30.08.23		EQS-News: Formycon reports successful first half of 2023
29.08.23		EQS-News: Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)
23.08.23		EQS-News: Formycon hosts conference call on financial and earnings position for H1 2023
23.08.23		EQS-News: Formycon veranstaltet Telefonkonferenz zur Finanz- und Ertragslage des 1. Halbjahres 2023
07.08.23		EQS-News: Formycon and Fresenius Kabi secure U.S. License Date for proposed Ustekinumab Biosimilar
07.08.23		EQS-News: Formycon und Fresenius Kabi sichern U.S. Vermarktungsstart für Ustekinumab Biosimilar-Kandidat FYB202 durch Settlement-Vereinbarung
26.07.23		EQS-News: Formycon reports on the regular Annual General Meeting

30.08.23

EQS-News: Formycon berichtet über erfolgreiches erstes Halbjahr 2023

30.08.23

EQS-News: Formycon reports successful first half of 2023

29.08.23

EQS-News: Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)

23.08.23

EQS-News: Formycon hosts conference call on financial and earnings position for H1 2023

23.08.23

EQS-News: Formycon veranstaltet Telefonkonferenz zur Finanz- und Ertragslage des 1. Halbjahres 2023

07.08.23

EQS-News: Formycon and Fresenius Kabi secure U.S. License Date for proposed Ustekinumab Biosimilar

07.08.23

EQS-News: Formycon und Fresenius Kabi sichern U.S. Vermarktungsstart für Ustekinumab Biosimilar-Kandidat FYB202 durch Settlement-Vereinbarung

26.07.23

EQS-News: Formycon reports on the regular Annual General Meeting

20:09		Why Splunk Stock Popped Today
20:04		Brazil’s comptroller general alleges Vale corrupted inspection in Brumadinho case
20:00		The Latest Analyst Ratings for Teck Resources
20:00		Analyst Expectations for Marriott Intl's Future
20:00		Expert Ratings for Eversource Energy
20:00		Analyst Ratings for Canadian Pacific Kansas
20:00		Analyst Ratings for Camping World Holdings
20:00		New BRICS Members Solidify The Bloc’s Renewable Leadership
19:42		Why Amazon Stock Was Falling Today
19:39		AI Demand, Positive Chinese Market Boost Micron's Pricing Dynamics Ahead Of Earnings, Says Analyst
19:34		Looking At Duke Energy's Recent Unusual Options Activity
19:30		Chevron Agrees To Terms That Could End Strike At LNG Facilities
19:18		Goldman Sachs Gr Unusual Options Activity
19:17		Check Out What Whales Are Doing With DIS
19:16		Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
19:16		Pennsylvania's Farm-To-Table Cannabis Bill, Big Tobacco VS. Illicit Market And More
19:11		FTC lawsuit targets serial acquisitions by private equity
19:11		FTC lawsuit targets serial acquisitions by private equity
19:07		Lina Khan: It’s time to halt roll-up schemes that violate antitrust laws
19:07		Help My Career: Want to avoid a toxic workplace? 5 questions to ask before you get hired.
19:05		: Here’s why Cisco is buying Splunk in a $28 billion deal
19:02		Looking At Intuitive Surgical's Recent Unusual Options Activity
19:02		What's Going On With Charles Schwab (SCHW) Shares
19:02		Guess? Takes Flight: Analyst Applauds Expansion Into Luggage And Highlights Brand's Potential To Dominate Fall Fashion Trends
19:01		Why Robinhood Markets Stock Is Moving
19:01		Weihenstephan und Sachsenmilch rufen Frischmilch zurück
19:01		The Latest Analyst Ratings for Driven Brands Hldgs
19:00		What 41 Analyst Ratings Have To Say About Salesforce
19:00		Oppenheimer Maintains Outperform Rating for SPX Techs: Here's What You Need To Know
19:00		The Latest Analyst Ratings for Warner Music Gr
19:00		Stifel Maintains Buy Rating for Revolution Medicines: Here's What You Need To Know
19:00		What 5 Analyst Ratings Have To Say About Constellation Energy
19:00		HC Wainwright & Co. Maintains Buy Rating for MediWound: Here's What You Need To Know
19:00		Expert Ratings for Scorpio Tankers
19:00		Baird Maintains Outperform Rating for WEX: Here's What You Need To Know
19:00		Morgan Stanley Maintains Overweight Rating for American Electric Power: Here's What You Need To Know
19:00		Amazon Wants to Keep the Cloud Healthy
19:00		What's Going On With Bank Of America Shares
19:00		EBay May Make Deliveries Via Drone and Bus
19:00		Citigroup Maintains Buy Rating for BeiGene: Here's What You Need To Know
19:00		Oracle's Patent Could Break AI's Black Box
19:00		MBS To Fox: Saudi Arabia Will Get Nuclear Arms If Iran Does
19:00		UK FCA gives unregistered crypto firms ‘final warning’ on ads regime compliance
18:59		Yes, It's Legal For NJ Cops To Use Weed Off-Duty, Another Case Confirms No Conflict With Fed Law
18:53		VW-Werk in Dresden: Gläserne Manufaktur produziert vorerst weiter
18:53		KB Home's Q3 Earnings Beat Expectations, But Analysts Cautious On Q4 Margins
18:47		Shiba Inu Drops To Floor Of Rising Channel, Attempts To Jump: The Bull, Bear Case
18:46		Sigma Lithium inks supply deal with Glencore with shipment prepared
18:45		Mercedes-Benz: Mega-Prozess im Dieselskandal startet kommende Woche
18:43		Creatio’s 8.1 Quantum low-code platform bolsters composable app development

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Formycon Aktie VALOR 12194189 / ISIN DE000A1EWVY8

Formycon Times and Sales (BRX)

Times and Sales

Eintrag hinzufügen Eintrag bearbeiten

Nachrichten zu Formycon AG

Analysen zu Formycon AG

Weitere Meldungen